|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert Davidson says there have been significant advances in clinical development of this novel drug delivery system, and the technology is rapidly moving from just a theory to practical real-world application.
|
|
|
Anish Parikh charts the twin rise of biologics and PFS, outlines some of the common challenges associated with filling and dispensing, and discusses how a patient-centric partnership approach can help biopharmaceutical companies shorten the development pathway and ensure a reliable supply of safe, effective medicines for the people who need them.
|
|
|
Gayatri Khanvilkar, MPharm, Ajit Bhagat, Sangmesh Torne, PhD, Tejas Gunjikar, PhD, and Amina Faham, PhD, present a case study showing that previously unviable APIs can be successfully processed with the right methods, which should give hope to formulators facing similar difficulties.
|
|
|
John S. Vrettos, PhD, says numerous technologies are currently in development that are designed to enable the oral delivery of peptides. Though each has its unique set of properties and capabilities, all must overcome key obstacles to successfully deliver peptides via the oral route.
|
|
|
|
|
|
|
|
|

Now employing over 900 people, the publicly listed (6472.TWO) Bora Pharmaceuticals is a premier, international, CGMP, CDMO specializing in complex oral solid dose (tablet, granules & capsules), liquids (solutions, suspensions, & nasal sprays) and semisolid (creams, lotions & gels) pharmaceutical Rx and OTC products for late-phase Clinical through Commercial manufacturing and packaging. Bora owns and operates three state-of-the-art CGMP manufacturing facilities in Taiwan and Canada that are built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. Click here for more.
|
|
|
|
|
|
 |
|
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced it has acquired Drug Delivery Experts, LLC (DDE)…..
|
|
 |
|
CatSci Ltd and Argonaute RNA recently announced a chemistry, manufacturing, and control (CMC) development collaboration focused on novel therapeutic oligonucleotides…..
|
|
 |
|
Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….
|
|
 |
|
Organon and ObsEva recently announced they have entered into an agreement whereby Organon will license the global development, manufacturing, and commercial rights to ebopiprant….
|
|
 |
|
Abzena and BioXpress Therapeutics recently announced their partnership to support biosimilar development for third-party customers. The partnership creates an….
|
|
|
|
|
Upcoming eNewsletter Features:
August 11 – Analytical Testing
August 18 – ODT/Fast Dissolve
|
|
|
|
|
|
|
|